A detailed history of Golden State Equity Partners transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Golden State Equity Partners holds 1,700 shares of CNTA stock, worth $30,923. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,700
Holding current value
$30,923
% of portfolio
0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$8.58 - $16.99 $14,586 - $28,882
1,700 New
1,700 $27,000
Q1 2023

Jun 01, 2023

SELL
$3.03 - $4.0 $48,389 - $63,880
-15,970 Closed
0 $0
Q1 2022

May 18, 2022

BUY
$7.45 - $11.59 $118,976 - $185,092
15,970 New
15,970 $143,000
Q1 2022

May 16, 2022

SELL
$7.45 - $11.59 $103,331 - $160,753
-13,870 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$10.99 - $17.54 $152,431 - $243,279
13,870 New
13,870 $156,000

Others Institutions Holding CNTA

About Centessa Pharmaceuticals plc


  • Ticker CNTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,339,296
  • Market Cap $1.72B
  • Description
  • Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...
More about CNTA
Track This Portfolio

Track Golden State Equity Partners Portfolio

Follow Golden State Equity Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Golden State Equity Partners, based on Form 13F filings with the SEC.

News

Stay updated on Golden State Equity Partners with notifications on news.